with surgeons and interventionalists to develop the next generation of synthetic cardiovascular devices From expandable vascular grafts to synthetic transcatheter valves PECA Labs focuses on imp ID: 829501
Download Pdf The PPT/PDF document "...utilizes a model of direct collaborat..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1 ...utilizes a model of direct collaborat
...utilizes a model of direct collaboration with surgeons and interventionalists to develop the next generation of synthetic cardiovascular devices. From expandable vascular grafts to synthetic transcatheter valves, PECA Labs focuses on improving outcomes through innovative technologies. www.PECALabs.com R The technologies described in this document are in development and are not available for clinical use All Materials 2017. PECA Labs & designs are trademarks of PECA Labs. The technologies described he
2 re are not available for sale or clinica
re are not available for sale or clinical use. c The First Controllably-Expandable Vascular Graft PECA Labs has developed a synthetic vascular graft that is capable of controlled expansion with a standard angioplasty balloon. The expandable vascular conduit is capable of providing conduit growth potential of over 250% while maintaining its suture retention strength, burst strength, kink radius, and other critical properties. The expandable vascular conduit utilizes a bioinert material with well-known c
3 linical performance, and capitalizes on
linical performance, and capitalizes on a unique microstructure to provide capabilities beyond any currently marketed vascular graft. www.PECALabs.com Expandable Vascular Conduit 2 R EXPAND Balloon at 2 ATM Balloon at 6 ATM Balloon Removed The technologies described in this document are in development and are not available for clinical use www.PECALabs.com The MASA Valve 3 R The First Synthetic Valved Conduit for RVOTR IMPROVE PECA Labs has developed a synthetic valved conduit for pediatric right ventricula
4 r out�ow tract reconstructio
r out�ow tract reconstruction (RVOTR): the MASA Valve. The MASA Valve utilizes synthetic materials to avoid the problems of immune response and calci�cation which are inherent to biologic valved conduits. After more than 5 years of implants in over 70 patients with intra-operative construction 1 of an equivalent design, the MASA Valve has shown statistically-signi�cant improvements in rates of reoperation and reintervention compared to homograft. The MASA Valve Freedom f
5 rom Reoperation in Patients Year Old The
rom Reoperation in Patients Year Old The technologies described in this document are in development and are not available for clinical use 1 Mid-term data presented at: 2011 Society of Thoracic Surgeons Annual Meeting by Yoshida, M; Bernstein, D. et. al. “Midterm Results for Bicuspid Valved PTFE Con - duit for Right Ventricular Outflow Tract Reconstruction.” www.PECALabs.com Synthetic Transcatheter Valve 4 R PECA Labs is developing a transcatheter valve that utilizes fully-synthetic materials towa
6 rds providing longevity beyond current
rds providing longevity beyond current options, which all utilize biologic valves. The synthetic transcatheter valve features a lea�et material which has a known bio-inert pro�le, and an advanced microstructure to provide excellent strength and stability. Although still in development, early testing with PECA’s synthetic transcatheter valve has demonstrated that the design and materials can withstand the most extreme hypertensive pressures without loss of integrity or function.
7 The First Fully-Synthetic Transcatheter
The First Fully-Synthetic Transcatheter Valve PERSIST Deployed Crimped The technologies described in this document are in development and are not available for clinical use Who We Are www.PECALabs.com Who We Are 5 PECA Labs is a spin-off of Carnegie Mellon University and the University of Pittsburgh. Our passion is the development of improved devices for cardiothoracic and vascular surgery. Founded in 2012, PECA’s original focus on surgical devices to improve the treatment of congenital heart defects h
8 as since broadened into the research an
as since broadened into the research and development of an array of cardiovascular surgical devices. Our model of direct collaboration with surgeons from around the globe is fueling the development of groundbreaking new devices, from expandable vascular conduits to synthetic transcatheter valves. R R MM002 Rev. 02 Contact Us TEL: +1.412.482.3755 TEL: +1.877.842.2873 FAX: +1.412.228.5868 TEL: +1.877.581.9945 4424 Penn Ave. STE 201 Pittsburgh, PA 15224 USA peca@pecalabs.com www.pecalabs.com www.PECALabs.com